Stock market analyst Mitesh Thacker has maintained 'buy' rating on Sun Pharmaceutical Industries Limited stock with a target of Rs 1900.

According to analyst, the stock can be purchased with a strict stop loss of Rs 1814.

The stock of the company, on Sep 16, closed at Rs 1836.40 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 1846 and a low of Rs 1187.30 on BSE.

Current EPS & P/E ratio stood at 84.56 and 22.07 respectively.

Sun Pharmaceuticals Ltd declared that a new proposal for stockholders of Israel-based Taro, even as its subsisting tender offer for the firm concluded on Wednesday.

At the finishing of the proposal, around 29,382 ordinary scrips, or 0.07% of Taro's scrip, which were outstanding, had been tendered.

Dilip Shanghvi, chairman and managing director of Sun Pharma stated, "Sun is pleased to be able to finally close the Offer."

But, the scrips owned by Levitts promoters' have not been tendered thus far.

On Sep 01, drug manufacturer Sun Pharmaceutical Ind Ltd bagged USFDA nod to market generic strattera caps in the US market.

These capsules are used for curing attention deficit hyperactivity trouble.